Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Preferred Stock Liabilities: 2018

  • Bicycle Therapeutics' Preferred Stock Liabilities was N/A to $54.6 million in Q4 2018 from the same period last year, while for Dec 2018 it was $54.6 million, marking a year-over-year change of. This contributed to the annual value of $54.6 million for FY2018, which is negligibly% changed negligibly from last year.
  • As of Q4 2018, Bicycle Therapeutics' Preferred Stock Liabilities stood at $54.6 million, which was down 0.00% from $54.6 million recorded in Q2 2018.
  • Over the past 5 years, Bicycle Therapeutics' Preferred Stock Liabilities peaked at $54.6 million during Q2 2018, and registered a low of $54.6 million during Q2 2018.
  • In the last 1 years, Bicycle Therapeutics' Preferred Stock Liabilities had a median value of $54.6 million in 2018 and averaged $54.6 million.